Non-invasive molecular imaging techniques may play a future role in the management of pulmonary hypertension. a) Positron emission tomography–computed.

Slides:

Advertisements

Similar presentations

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Advertisements

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

a) Normal parasternal long-axis view.

A 45-year-old with pulmonary hypertension

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

Right sleeve pneumonectomy for T4 squamous cell carcinoma

The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

A) Pressure tracings from the aorta (AO) and pulmonary artery (PA), demonstrating systemic levels of pulmonary arterial pressures. a) Pressure tracings.

Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Positron emission tomography/computed tomography scans showed a mass lesion. a) Areas of cavitation were noted in the left lower lobe, encasing the segmental.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Elastic staining of paraffin-embedded lung tissue.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

A) 18-fluorodeoxyglucose positron emission tomography-computed tomography in a 72-year-old male revealed pulmonary nodules in the lower lobes. a) 18-fluorodeoxyglucose.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Multimodality imaging of aortic stenosis.

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

A pump function graph demonstrating mean right ventricular pressure as a function of stroke volume (SV). A pump function graph demonstrating mean right.

Haemodynamic response to exercise in a) normal subjects and b) Fontan patients. Haemodynamic response to exercise in a) normal subjects and b) Fontan patients.

A 50-year-old male with persistent abnormality on computed tomography (CT) despite anticoagulation for 1 year. a) CT scan showing an expansile low attenuation.

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Conceptual model of the ageing Fontan circulation

Cardiac magnetic resonance imaging of the heart in a patient with pulmonary arterial hypertension. a) Short axis image. #: dilated right ventricle; ¶:

A) Positron emission tomography scan showing 18F-fluorodeoxyglucose uptake in the right supraclavicular, hilar and mediastinal lymph nodes and in the left.

Kaplan–Meier survival curves for baseline cardiac magnetic resonance imaging variables according to the median value in patients with pulmonary hypertension.

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Laplace's law: T = (P×r)/2h.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

a) Segmentation of pulmonary arteries according to Cabrol

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

Tissue Doppler imaging (TDI) of the basal part of the right ventricle free wall allows the measurements on a single cardiac cycle of several parameters.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Effect of riociguat on a) right heart hypertrophy (assessed by the ratio of right ventricle weight to left ventricle and septum weight (RV/(LV+S)) and.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

A) Micro-computed tomography data corresponding to a helium-3 magnetic resonance imaging voxel size of 7×7×7 mm and b) the segmented single acinus volume.

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Investigation of suspected idiopathic pulmonary fibrosis: multidisciplinary team (MDT) discussion is a key component of the diagnostic pathway. Investigation.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Algorithm for diagnosis and treatment of reported cases.

Images from a 62-year-old male patient presenting with a heterogeneous mass in the superior lobe of the right lung. a) Fusion of axial fat-saturated T1-weighted.

Abdominal magnetic resonance imaging of a patient with tuberous sclerosis complex lymphangioleiomyomatosis and multiple small renal angiomyolipomas (arrows)

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

A 53-year-old patient with fibrosing mediastinitis

A) Chest radiograph of a 37-year-old male mountaineer with high-altitude pulmonary oedema (HAPE) showing a patchy to confluent distribution of oedema,

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Flow–volume loops of test breaths and preceding control breaths of a representative chronic obstructive pulmonary disease patient with different degrees.

Flow–volume loops of test breaths and preceding control breaths of three representative chronic obstructive pulmonary disease patients with different degrees.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

A) Chest computed tomography image showing left upper lobe cavitary lesion consistent with invasive pulmonary aspergillosis (IPA) in an allogeneic haematopoietic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Non-invasive molecular imaging techniques may play a future role in the management of pulmonary hypertension. a) Positron emission tomography–computed tomography shows increased 18F-fluorodeoxyglucose uptake in the right ventricular wall (arrow) in pulmonar... Non-invasive molecular imaging techniques may play a future role in the management of pulmonary hypertension. a) Positron emission tomography–computed tomography shows increased 18F-fluorodeoxyglucose uptake in the right ventricular wall (arrow) in pulmonary hypertension; reproduced and modified from [93] with permission. b) Magnetic resonance imaging (MRI) shows advanced structure of heart fused with positron emission tomography to determine 18F-fluorodeoxyglucose uptake in areas with high metabolic activity; reproduced from [94] with permission. c) Four-dimensional flow MRI as a measure of complex three-dimensional haemodynamic changes in the pulmonary arteries; reproduced from [95] with permission. d) Cardiac hyperpolarised MRI shows the distribution of injected hyperpolarised pyruvate and its metabolic conversion to bicarbonate and lactate to visualise areas of high metabolic activity; reproduced from [96] with permission. PA: pulmonary artery. Stephen Y. Chan, and Lewis J. Rubin Eur Respir Rev 2017;26:170094 ©2017 by European Respiratory Society